In the U.S., incidence rates of some cancers have increased in 15- to 49-year-olds with concomitant increases in older age groups, suggesting that changes in risk factor prevalence and/or improvements ...

2018 Meetings Abstracts: Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic January 8–11, 2018; San Diego, CA Proceedings: AACR Annual ...

Abstract. This study presents national- and state-level prevalence of major modifiable cancer risk factors, human papillomavirus vaccination, and cancer screenings among US adults in the years during ...

AACR Journals Blood Cancer Discovery Cancer Discovery Cancer Epidemiology, Biomarkers & Prevention Cancer Immunology Research Cancer Prevention Research Cancer Research Cancer Research Communications ...

AACR Journals Blood Cancer Discovery Cancer Discovery Cancer Epidemiology, Biomarkers & Prevention Cancer Immunology Research Cancer Prevention Research Cancer Research Cancer Research Communications ...

2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 ...

1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 ...

1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 ...

Abstract. Nearly a quarter century ago, Hanahan and Weinberg conceived six unifying principles explaining how normal cells transform into malignant tumors. Their provisional set of biological ...

Targeting KRAS in pancreatic cancer induces a resistant, highly differentiated cell state that serves as a reservoir for disease relapse, and cytoablative strategies aimed at this state offer a novel ...

Chimeric antigen receptor (CAR) T-cell therapy is a potent immunotherapy for hematologic malignancies, but patients can develop long-term adverse events, including second primary malignancies (SPM) ...

Abstract. In solid tumors, three main complementary approaches of adoptive T-cell therapies were successively developed: tumor-infiltrating lymphocytes, chimeric antigen receptor engineered T cells, ...